ReCode Therapeutics to Present at September Investor Conferences

 

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage company powering the next wave of genetic medicines, today announced that Company management will participate in the following upcoming investor conferences in September 2023:

Morgan Stanley Global Healthcare Conference:
Format: Company Presentation
Date: September 12, 2023
Time: 12:55 p.m. ET
Presenter: David J. Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics
Location: New York, NY

Jefferies Cell & Genetic Medicine Summit
Format: Company Presentation
Date: September 26, 2023
Time: 10:30 a.m. ET
Presenter: David J. Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics
Location: New York, NY

BMO Biopharma Spotlight Series: Latest Advances in Genome/Epigenome Editing
Format: Panel Discussion - Novel Approaches in Gene Editing and Delivery
Date: September 26, 2023
Time: 2:30 p.m. ET
Presenter: Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics
Location: Virtual

About ReCode Therapeutics

ReCode Therapeutics is a clinical-stage company powering the next wave of genetic medicines. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. ReCode’s lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells. In 2022, ReCode was named among Fierce Biotech’s “Fierce 15” as one of the most promising early-stage biotechnology companies in the industry and was described by Nature as one of the “Seven Technologies to Watch in 2022” for its SORT LNP platform. For more information, visit www.recodetx.com and follow us on LinkedIn.

Contacts

Investor Contact:
Anne Marie Fields
Stern IR
annemarie.fields@sternir.com
IR@recodetx.com

Media Contact:

Erica Jefferson
ReCode Therapeutics
ejefferson@recodetx.com
650- 629-7965

Tara Cooper
The Grace Communication Group
tara@gracegroup.us
650-303-7306

 
 

Source: ReCode Therapeutics

Back to news